Adverse events self-reported by patients with extensive-stage small-cell lung cancer in the phase III CASPIAN study
Authors
- Nenad Medić (ORCID: https://orcid.org/0000-0002-4914-334X)
- Mustafa Özgüroğlu (ORCID: https://orcid.org/0000-0002-8417-8628)
- Jonathan Wade Goldman (ORCID: https://orcid.org/0000-0002-4925-8243)
- P. Chugh
- Luis Paz‐Ares (ORCID: https://orcid.org/0000-0002-1947-3364)
- Yuanbin Chen (ORCID: https://orcid.org/0009-0006-4175-8055)
- Helen Mann
- Marina Chiara Garassino (ORCID: https://orcid.org/0000-0002-3821-5598)
- Tapashi Dalvi
Institutions
- AstraZeneca (United Kingdom) (GB)
- Istanbul University-Cerrahpaşa (TR)
- AstraZeneca (Brazil) (BR)
- Hematology Oncology Consultants (US)
- Fondazione IRCCS Istituto Nazionale dei Tumori (IT)